(Q45959241)

English

Multicenter phase II study of everolimus in patients with metastatic or recurrent bone and soft-tissue sarcomas after failure of anthracycline and ifosfamide.

scientific article published on 14 September 2013

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24037083%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

Multicenter phase II study of everolimus in patients with metastatic or recurrent bone and soft-tissue sarcomas after failure of anthracycline and ifosfamide (English)

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24037083%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24037083%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

author name string

Changhoon Yoo

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24037083%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

Jeeyun Lee

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24037083%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

Kyong Hwa Park

4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24037083%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

Tae Min Kim

5

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24037083%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

Yu Jung Kim

6

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24037083%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

Hyo Jin Lee

7

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24037083%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

Kyung Hee Lee

8

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24037083%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

Jin-Hee Ahn

9

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24037083%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

publication date

14 September 2013

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24037083%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

Investigational New Drugs

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24037083%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

31

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24037083%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

6

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24037083%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

1602-1608

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24037083%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

https://scigraph.springernature.com/pub.10.1007/s10637-013-0028-7

0 references

Cancer statistics, 2013

1 reference

https://api.crossref.org/works/10.1007%2FS10637-013-0028-7

21 January 2018

Randomized phase II study of gemcitabine and docetaxel compared with gemcitabine alone in patients with metastatic soft tissue sarcomas: results of sarcoma alliance for research through collaboration study 002 [corrected].

1 reference

https://api.crossref.org/works/10.1007%2FS10637-013-0028-7

21 January 2018

Phase II trial of weekly paclitaxel for unresectable angiosarcoma: the ANGIOTAX Study

1 reference

https://api.crossref.org/works/10.1007%2FS10637-013-0028-7

21 January 2018

Gemcitabine and vinorelbine combination chemotherapy for patients with advanced soft tissue sarcomas: results of a phase II trial.

1 reference

https://api.crossref.org/works/10.1007%2FS10637-013-0028-7

21 January 2018

Efficacy of trabectedin (ecteinascidin-743) in advanced pretreated myxoid liposarcomas: a retrospective study

1 reference

https://api.crossref.org/works/10.1007%2FS10637-013-0028-7

21 January 2018

Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors

1 reference

https://api.crossref.org/works/10.1007%2FS10637-013-0028-7

21 January 2018

Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial

1 reference

https://api.crossref.org/works/10.1007%2FS10637-013-0028-7

21 January 2018

The biology behind mTOR inhibition in sarcoma

1 reference

https://api.crossref.org/works/10.1007%2FS10637-013-0028-7

21 January 2018

Advances in sarcoma genomics and new therapeutic targets

1 reference

https://api.crossref.org/works/10.1007%2FS10637-013-0028-7

21 January 2018

Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial

1 reference

https://api.crossref.org/works/10.1007%2FS10637-013-0028-7

21 January 2018

Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer

1 reference

https://api.crossref.org/works/10.1007%2FS10637-013-0028-7

21 January 2018

Everolimus for advanced pancreatic neuroendocrine tumors.

1 reference

https://api.crossref.org/works/10.1007%2FS10637-013-0028-7

21 January 2018

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

1 reference

https://api.crossref.org/works/10.1007%2FS10637-013-0028-7

21 January 2018

A phase 2 study of temsirolimus (CCI-779) in patients with soft tissue sarcomas: a study of the Mayo phase 2 consortium (P2C).

1 reference

https://api.crossref.org/works/10.1007%2FS10637-013-0028-7

21 January 2018

Phase II study of the mammalian target of rapamycin inhibitor ridaforolimus in patients with advanced bone and soft tissue sarcomas

1 reference

https://api.crossref.org/works/10.1007%2FS10637-013-0028-7

21 January 2018

Phase II multicenter trial of imatinib in 10 histologic subtypes of sarcoma using a bayesian hierarchical statistical model.

1 reference

https://api.crossref.org/works/10.1007%2FS10637-013-0028-7

21 January 2018

Multicenter phase II trial of sunitinib in the treatment of nongastrointestinal stromal tumor sarcomas.

1 reference

https://api.crossref.org/works/10.1007%2FS10637-013-0028-7

21 January 2018

Phase II study of sorafenib in patients with metastatic or recurrent sarcomas.

1 reference

https://api.crossref.org/works/10.1007%2FS10637-013-0028-7

21 January 2018

Pazopanib, a multikinase angiogenesis inhibitor, in patients with relapsed or refractory advanced soft tissue sarcoma: a phase II study from the European organisation for research and treatment of cancer-soft tissue and bone sarcoma group (EORTC stu

1 reference

https://api.crossref.org/works/10.1007%2FS10637-013-0028-7

21 January 2018

Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial

1 reference

https://api.crossref.org/works/10.1007%2FS10637-013-0028-7

21 January 2018

Results of an international randomized phase III trial of the mammalian target of rapamycin inhibitor ridaforolimus versus placebo to control metastatic sarcomas in patients after benefit from prior chemotherapy

1 reference

https://api.crossref.org/works/10.1007%2FS10637-013-0028-7

21 January 2018

Cixutumumab and temsirolimus for patients with bone and soft-tissue sarcoma: a multicentre, open-label, phase 2 trial

1 reference

https://api.crossref.org/works/10.1007%2FS10637-013-0028-7

21 January 2018

The Combination of Sorafenib and Everolimus Abrogates mTORC1 and mTORC2 upregulation in osteosarcoma preclinical models.

1 reference

https://api.crossref.org/works/10.1007%2FS10637-013-0028-7

21 January 2018

Progression-free rate as the principal end-point for phase II trials in soft-tissue sarcomas

1 reference

https://pubmed.ncbi.nlm.nih.gov/24037083

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1007/S10637-013-0028-7

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24037083%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

Dimensions Publication ID

0 references

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24037083%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q45959241&oldid=1419737322"